|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.31 USD | +11.45% |
|
+24.44% | +233.50% |
| Apr. 18 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
| Mar. 06 | Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia | CI |
On August 12, 2019, Rezolute, Inc. (OTCPK:RZLT) closed the transaction. The company has amended the terms of the transaction. The company entered into a stock purchase agreement with an accredited investor and issued additional 13,103,448 common shares for gross proceeds of $3,799,999.92 in the second tranche of the transaction.
The company has issued 82,931,034 common shares for gross proceeds of $24,049,999.86 in the transaction.
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 13,590 KRW | -0.95% | +1.57% | 138M | ||
| 7,680 KRW | -0.13% | +5.49% | 235M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +233.50% | 133M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +38.61% | 12.63B | |
| +313.59% | 8.49B |
REZOLUTE, INC. 
